Try our beta test site
51 studies found for:    pkd
Show Display Options
Rank Status Study
21 Withdrawn Repository Study of Autosomal Dominant Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention:
22 Recruiting Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical Trial
Condition: Polycystic Kidney, Type 1 Autosomal Dominant Disease
Intervention: Procedure: Preimplantation Genetic Diagnosis
23 Completed Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease
Conditions: Chronic Renal Failure;   Polycystic Kidney Disease
Intervention: Biological: Intravenous injection autologous mesenchymal stem cells
24 Completed Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes
Condition: Diabetic Kidney Disease
Intervention:
25 Completed Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety
Condition: Polycystic Kidney
Interventions: Drug: Sirolimus;   Drug: conventional therapy
26 Completed Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Other: Water prescription
27 Completed Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease
Conditions: Chronic Kidney Disease;   Polycystic Kidney, Autosomal Dominant
Intervention:
28 Recruiting A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Drug: placebo
29 Completed Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus
Condition: Type1 Diabetes
Intervention: Drug: Insulin glargine new formulation HOE901
30 Completed Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects
Condition: Hypercholesterolemia
Interventions: Drug: Alirocumab;   Drug: Ezetimibe;   Drug: Ezetimibe Placebo;   Drug: Fenofibrate
31 Completed Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Lixisenatide (AVE0010);   Drug: Placebo
32 Completed Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Insulin glargine HOE901;   Drug: Insulin glargine - New formulation HOE901
33 Completed Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)
Condition: Hypercholesterolemia
Intervention: Drug: alirocumab SAR236553 (REGN727)
34 Completed Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)
Condition: Hypercholesterolemia
Intervention: Drug: alirocumab SAR236553 (REGN727)
35 Completed Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects
Condition: Hypercholesterolemia
Intervention: Drug: alirocumab SAR236553 (REGN727)
36 Terminated Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients
Condition: Infection Prophylaxis
Interventions: Drug: SAR279356;   Drug: placebo
37 Completed Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®
Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Insulin glargine (HOE901)
38 Completed Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects
Condition: Healthy
Interventions: Drug: CLOPIDOGREL;   Drug: placebo
39 Completed Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia
Condition: Sleep Initiation and Maintenance Disorders
Intervention: Drug: Eplivanserin (SR46349)
40 Recruiting UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource
Conditions: Hepato/Renal Fibrocystic Disease;   Autosomal Recessive Polycystic Kidney Disease;   Joubert Syndrome;   Bardet Biedl Syndrome;   Meckel-Gruber Syndrome;   Congenital Hepatic Fibrosis;   Caroli Syndrome;   Oro-Facial-Digital Syndrome Type I;   Nephronophthisis;   Glomerulocystic Kidney Disease
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-51) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.